EMAS position statement: Management of depressive symptoms in peri- and postmenopausal women

EMAS has just published a position statement in Maturitas. The perimenopause is considered to be a time of increased risk for the development of depressive symptoms and major depressive episodes especially in women who have a history of mood disorder. EMAS recommends that awareness of depressive symptoms, early detection, standardized diagnostic procedures, personalized treatment and…

Global Position Statement on testosterone treatment for women

The first Global Position Statement on the use of testosterone in the treatment of women, led by the International Menopause Society (IMS), was published in four leading international medical journals on 2 September 2019: Climacteric, Maturitas, The Journal of Sexual Medicine, and The Journal of Clinical Endocrinology and Metabolism. The statement has been authored by a diverse team of leading experts…

Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Collaborative Group on Hormonal Factors in Breast Cancer

30 August 2019 A meta-analysis covering the period January 1992 to January 2018 has been published in the Lancet by the Collaborative Group on Hormonal Factors in Breast Cancer. It has reported on the risk of breast cancer with MHT in relation to the type and timing of therapy. During prospective follow-up, 108 647 postmenopausal women…